贝瑞基因：全资子公司基于三代基因测序技术的检测试剂盒获得医疗器械注册证

Core Viewpoint - Berry Genomics (000710) has announced that its subsidiary, Hangzhou Berry Health and Technology Co., Ltd., has received the medical device registration certificate from the National Medical Products Administration (NMPA) for its α and β thalassemia gene testing kit, marking a significant milestone in the clinical application of third-generation sequencing technology [1] Group 1 - The gene testing kit utilizes single-molecule sequencing technology for the qualitative detection of thalassemia gene mutations in human peripheral venous whole blood samples [1] - The certification of the testing kit represents a critical breakthrough in both technology and strategy for Berry Genomics, facilitating the clinical transformation of its third-generation sequencing technology [1]